A number of COVID-19 detection companies forecast a net profit increase of more than 16 times

2022-05-03 0 By

Recently, a number of COVID-19 detection companies announced their 2021 annual performance forecasts.According to the incomplete statistics of Zhongxin Jingwei, the net profits of some companies have increased to varying degrees due to the surge in overseas demand for COVID-19 testing and the surge in sales of related testing products.January 19, “monster” Jiuan medical released performance forecast, 2021 is expected to achieve net profit of 900 million yuan – 1.2 billion yuan, a year-on-year increase of 271.40%-395.19%;In 2021, the company’s novel Coronavirus (SARS-CoV-2) antigen home self-testing OTC kit products enjoyed a significant increase in sales in the US market due to the continued impact of the global COVID-19 pandemic, which contributed to the significant growth in business performance in 2021.Jiuan’s share price jumped 11-fold in two months.Nine medical said Ann, kit products demand is directly related to the epidemic development situation, virus mutation, vaccination, aimed at the launch of the new champions drugs also affect the developments such as rate, so future outbreak has strong uncertainty, the uncertainty may significantly affect the kit product demand.In addition, a number of COVID-19 detection companies have also released pre-profit announcements.On January 4, Mingde biological announced that it is expected to achieve net profit of 1.3 billion yuan to 1.5 billion yuan in 2021, a year-on-year growth of 177.23% to 219.88%;Sales of nucleic acid testing reagents for COVID-19 increased significantly;On January 6, Reking Announced that it expects to achieve a net profit of 2 billion to 2.35 billion yuan in 2021, up 1684.65% to 1996.97% year on year.In the second half of 2021, the high COVID-19 epidemic in Europe, Southeast Asia and other countries and regions led to a significant increase in the demand for COVID-19 antigen testing reagents, and realized a significant increase in the revenue of COVID-19 testing reagents overseas.On January 14, Oriental Bio announced that it expects to achieve net profit of 4.72 billion yuan to 5.12 billion yuan in 2021, compared with the same period last year (statutory disclosure data), will increase by 3.043 billion yuan to 3.443 billion yuan, a year-on-year increase of 181.45% to 205.31%.The number of COVID-19 tests is also expected to remain at a record high, judging from the record number of new confirmed cases around the world, said Principal Securities.”The global nucleic acid testing market is rising with the rebound of the global epidemic and the growing demand of the overseas antigen testing market.”However, Sinolink Securities research report also pointed out that in terms of risks, global epidemic relief and supply expansion overlay, detection product volume and price ushered in a downward trend, or will face the deterioration of the competitive landscape and business development as expected risks.